Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L, Pietilä EA, Turunen SP, Corvigno S, Hjerpe E, Bulanova D, Joneborg U, Alkasalias T, Miki Y, Yashiro M, Chernenko A, Jukonen J, Singh M, Dahlstrand H, Carlson JW, Lehti K. Moyano-Galceran L, et al. Among authors: lehti k. EMBO Mol Med. 2020 Apr 7;12(4):e11177. doi: 10.15252/emmm.201911177. Epub 2020 Mar 2. EMBO Mol Med. 2020. PMID: 32115889 Free PMC article.
RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivo.
Alkasalias T, Alexeyenko A, Hennig K, Danielsson F, Lebbink RJ, Fielden M, Turunen SP, Lehti K, Kashuba V, Madapura HS, Bozoky B, Lundberg E, Balland M, Guvén H, Klein G, Gad AK, Pavlova T. Alkasalias T, et al. Among authors: lehti k. Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1413-E1421. doi: 10.1073/pnas.1621161114. Epub 2017 Feb 7. Proc Natl Acad Sci U S A. 2017. PMID: 28174275 Free PMC article.
A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L. Tumiati M, et al. Among authors: lehti k. Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1. Clin Cancer Res. 2018. PMID: 29858219
Fibroblasts in the Tumor Microenvironment: Shield or Spear?
Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K. Alkasalias T, et al. Among authors: lehti k. Int J Mol Sci. 2018 May 21;19(5):1532. doi: 10.3390/ijms19051532. Int J Mol Sci. 2018. PMID: 29883428 Free PMC article. Review.
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.
Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW. Binzer-Panchal A, et al. Among authors: lehti k. Clin Cancer Res. 2019 Apr 1;25(7):2155-2165. doi: 10.1158/1078-0432.CCR-18-2792. Epub 2019 Jan 7. Clin Cancer Res. 2019. PMID: 30617134
Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization.
Le Joncour V, Filppu P, Hyvönen M, Holopainen M, Turunen SP, Sihto H, Burghardt I, Joensuu H, Tynninen O, Jääskeläinen J, Weller M, Lehti K, Käkelä R, Laakkonen P. Le Joncour V, et al. Among authors: lehti k. EMBO Mol Med. 2019 Jun;11(6):e9034. doi: 10.15252/emmm.201809034. EMBO Mol Med. 2019. PMID: 31068339 Free PMC article.
99 results